Incisive Genetics Inc. (IG) is a Canadian biotech firm that is focused on developing its innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe the proprietary Incisive Delivery System™ provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe delivery of active gene editing machinery into in vivo target tissues.Learn more
There is a unique opportunity in the gene therapy space for development of a “true” platform delivery technology. We will develop therapeutics comprised of:our proprietary OmniaTM platform, active CRISPR proteins, such as Cas9, and the target-specific guideRNA (and DNA template molecules when required). Incisive Genetics’ OmniaTM platform is a proprietary, non-viral delivery method for CRISPR-based gene therapies.Learn more
There is a unique opportunity in the gene therapy space for development of a superior platform delivery technology. The Incisive Delivery System™ is a proprietary, non viral delivery method for CRISPR based gene therapies. We intend to continue developing therapeutics using our proprietary platform, active CRISPR proteins, such as Cas9, and the target-specific guide RNA (and DNA template molecules when required).Learn more
Dr. Leavitt is a world-renowned translational neuroscientist and accomplished neurologist with extensive experience in both...
Dr. Kevin Chow has over two decades of experience leading business development and corporate strategy in both large and small biopharmaceutical companies.
Mr. Hill is Director of Business Development at Incisive Genetics Inc. He co-founded the company and co-invented the Incisive Delivery System™.
Pamela Wagner is the Director of R&D Operations at Incisive Genetics Inc. She co-founded the company and co-invented the Incisive Delivery System™.
Karen Boodram has over 30 years’ experience in the pharmaceutical and biotech sectors, specializing in the commercialization of pharmaceutical products.
Dr. Hayden is a Killam Professor at the University of British Columbia, the highest honour UBC can confer on any faculty member. He is also an accomplished scientist and physician. He was the President of Global R&D...
Dr. Thompson is currently Donald Bren and Chancellor’s Professor in the Departments of Psychiatry and Human Behavior and Neurobiology and Behavior at the University of California Irvine.
The financing syndicate was led by investors Noel Hall and Sandra MacPherson of the MacHall group and Haig Farris, OC.
IG today announced the formation of its Scientific Advisory Board (SAB) and the appointment of Dr. Michael R. Hayden as chairperson.